, median prior lines of treatment [LoT], percentage of patients with high- risk
cytogenetic abnormalities [HRCAs] and who underwent autologous haematopoietic stem cell
[CITATION][C] Safety profile of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta-analysis of proportions …
Published: 06/18/2026